Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome

- Clinical evidence for unique Ranexa(R) mechanism of action - PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the Journal of Cardiovascular Electrophysiology has published a study of ranolazine showing that ranolazine signi...

Angina drug potentially useful against heart rhythm disorders

...rrent, pilot study, researchers found that a drug, ranolazine (brand name Ranexa, CV Therapeutics) shortens the ...of Rochester Medical Center and lead author on the ranolazine abstract. Our study found that we may be able to ...for the price of one with this drug. Specifically, ranolazine shortens the QTc interval and improves myocardial ...

FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)

...isk of ventricular tachycardia lasting eight beats or more (p<0.001) and there were fewer episodes of sudden cardiac death observed in patients taking ranolazine (56) than in patients taking placebo (65). In accordance with a special protocol assessment agreement between the FDA and CV Therapeutics, the Compa...

Ranexa(R) Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study

...nce in symptomatic documented arrhythmias was observed in women between the ranolazine and placebo groups. The data were presented today by Dr. Jessica Mega of t...ckers or nitrates. Study Design MERLIN TIMI-36 (Metabolic Efficiency with ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi...

Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP

...ociation Scientific Sessions in Orlando, Florida. ranolazine is believed to exert its anti-ischemic effects thr...dromes (ACS). "The potential enhanced efficacy of ranolazine in patients with elevated BNP in this analysis is ...guing to see the potentially beneficial effects of ranolazine in this group of MERLIN TIMI-36 patients," Morrow ...

Anti-anginal Drug Not Effective in Reducing Major Cardiac Events

... Despite being safe, anti-anginal medication ranolazine has not been effective in reducing the risk of maj...current events remains substantial. The medication ranolazine is used for patients with chronic angina, but because of an association between ranolazine and prolongation of the QT interval (a certain mea...

Reducing The Frequency Of Angina Attacks While Exercising

...hest pain sufferers exercise longer. When the drug ranolazine was taken // with other antianginal medications it...d dose of frequently prescribed antianginal drugs, ranolazine can reduce both the angina frequency and nitroglyc...n increased by nearly two minutes for those in the ranolazine therapy group compared with 90 seconds for those t...

New Medication May Decrease The Frequency Of Angina Attacks

...ing to new research. Researchers say when the drug ranolazine is taken with other antianginal medications, it im...d dose of frequently prescribed antianginal drugs, ranolazine can reduce both the angina frequency and nitroglyc...n increased by nearly two minutes for those in the ranolazine therapy group compared with 90 seconds for those t...

Ranolazine in Medical Technology

European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina

PALO ALTO, Calif., April 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending approval of ranolazine in the European...

CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina

...atients. "MERLIN-TIMI 36 is the largest study of ranolazine in patients with established coronary artery disea...tients than those studied previously and reaffirms ranolazine as an option for treating chronic angina." Study...Design MERLIN-TIMI 36 (Metabolic Efficiency with ranolazine for Less Ischemia in Non-ST Elevation Acute Corona...

New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion

...h Annual Scientific Session in Chicago showed that ranolazine increased glucose-stimulated insulin secretion (GS...mpany believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant re...manner in isolated islets. Acute administration of ranolazine to animals also significantly increased GSIS in th...

Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder

...eutics, Inc. (Nasdaq: CVTX ) announced today that ranolazine significantly (p<0.001) shortened the QT interval ...ith heart rhythm problems, including sudden death. ranolazine also shortened cardiac relaxation time in the stud...have a defect in the specific sodium channel where ranolazine has its activity, it makes sense that we are seein...

CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

...e results of the MERLIN TIMI-36 study confirm that ranolazine is a safe and effective anti-ischemic drug that al... Design MERLIN TIMI-36 (Metabolic Efficiency with ranolazine for Less Ischemia in Non-ST Elevation Acute Corona...ism of action of Ranexa in diabetes has shown that ranolazine increased glucose stimulated insulin secretion in ...

CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007

...tion Reserve Unmasks the Role of Late Sodium Current in Rabbit Isolated Hearts; Poster, Sunday, September 2, 8:30 a.m. - 12:30 p.m. CEST Mechanism of ranolazine Block of Cardiac Na Channels; Poster, Monday, September 3, 2:00 - 6:00 p.m. CEST Regadenoson Results from Two Randomized, Double-blind, Placebo-cont...

CV Therapeutics Announces Topline MERLIN TIMI-36 Results

...d today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ran... in New Orleans. Study Design MERLIN TIMI-36 (Metabolic Efficiency with ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-...

JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program

...e of Cardiology (JACC) has published data from the ranolazine Open Label Experience (ROLE) program, which showed...icipation in the phase 3 Monotherapy Assessment of ranolazine In Stable Angina (MARISA) or the phase 3 Combination Assessment of ranolazine In Stable Angina (CARISA) clinical studies with Ra...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

...leted preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in ...ts using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis. These data co...cal trials. In CARISA (Combination Assessment of ranolazine in Stable Angina), Ranexa (ranolazine extended rel...

Ranolazine in Biological Technology

CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina

PALO ALTO, Calif., July 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that it has received marketing authorization from the European Medicines Agency (EMEA) for ranolazine for the treatment of patients with chronic angina in all 27 European Union (EU) memb...

CV Therapeutics Reports 2008 Third Quarter Financial Results

...of our convertible subordinated notes and $9.0 million to meet a milestone obligation to Roche Palo Alto LLC resulting from marketing authorization of ranolazine in the European Union. Additionally, the Company made an estimated tax payment of $10.3 million primarily as a result of the cash received from Menari...

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

...and also often have diabetes. Considering its mechanism of action, established cardiovascular safety and observed reductions in arrhythmias and HbA1c, ranolazine now becomes an even more important drug in our treatment of chronic angina," said Dr. Eugene Braunwald, Distinguished Hersey Professor of Medicine at ...

CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)

...ency (EMEA) for the brand name Ranexa(R) (ranolazine). On July 10, 2008, the Company announced that the EMEA had granted marketing authorization for ranolazine in all 27 European Union (EU) member states under the brand name Latixa. "Securing approval for the Ranexa brand name in Europe provides important b...

CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award

...injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately...

CV Therapeutics Reports 2008 Second Quarter Financial Results

...injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately...

CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008

...injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately...

CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session

...Ranexa(R) (ranolazine extended-release tablets): ranolazine Suppresses Ectopic Activity in Isolated Rat Left A...; Poster; Sunday, March 30, 2008, 10:00 a.m. CST ranolazine Attenuates Palmitoyl-L-Carnitine Induced Ventricul...; Poster, Sunday, March 30, 2008, 11:00 a.m. CST ranolazine Prevents Ischemia-Induced ST Segment Changes and L...

FDA Approves New Mechanism of Action Labeling for Ranexa(R)

...nistration (FDA) has approved new language for the product labeling for Ranexa(R) (ranolazine extended-release tablets) which describes the ability of ranolazine to inhibit the late sodium current at therapeutic levels. Published data on ranolazine's mechanism suggests that during ischemic episodes excess sod...

CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007

... EST B-type Natriuretic Peptide and the Effect of ranolazine in Patients with Non- ST Elevation Acute Coronary ... 5, 2007, 10:00 a.m. EST Anti-Ischemic Effects of ranolazine in Women: Results from the Randomized, Placebo-con...esday, November 6, 2007, 10:00 a.m. EST Effect of ranolazine on Hemoglobin A1c in the MERLIN TIMI-36 Randomized...